Location San Francisco, California, United States Regions San Francisco Bay Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Robert Booth, PhD, is currently the Chief Executive Officer of Virobay, Inc., a drug discovery and development company. Robert Booth was also the Executive Chairman of Virobay, Inc. from 2006 to 2010 and served concurrently as an Operating Partner and Senior Advisor at TPG Biotech, a venture capital company.
From 2006 to 2007, Robert Booth served
as the acting Chief Scientific Officer of Galleon Pharmaceuticals, a company which is developing new therapeutics for diseases of the respiratory system.
From 2002 to 2006, Robert Booth was the Chief Scientific Officer at Celera Genomics, where he was responsible for leading all discovery and development activities. The therapeutic areas pursued by Celera included oncology, autoimmunity, respiratory diseases and thrombosis.
Robert Booth was Senior Vice President at Roche Bioscience from 1989 to 2002, and was responsible for research and early development activities in the therapeutic areas of inflammation, autoimmunity, respiratory diseases, transplantation, bone diseases and viral diseases. Robert Booth was a member of the Global Research Management Team and a member of the Business Development Committee, which oversaw licensing opportunities for Roche.
During his time at Roche, Robert Booth managed R&D organizations in both the US and Europe. The Biology team for which Robert Booth was responsible in the UK discovered and contributed to the development of saquinavir, the first HIV protease inhibitor to be launched. This achievement was recognized by the winning of the Prix Galien for Roche.
Robert Booth is currently a member of the Scientific Advisory Board of ShangPharma, a large, privately held CRO in China. Robert Booth received his Ph.D. and B.Sc. from the University of London in the field of biochemistry.
